Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation

By LabMedica International staff writers
Posted on 23 Jul 2025

Early detection of cancer and other serious diseases is crucial for effective treatment and improved outcomes, yet current diagnostic methods often involve invasive procedures and complex sample preparation. More...

These barriers limit accessibility and delay diagnosis, particularly in low-resource settings. For example, detecting tumor-specific mutations typically requires blood samples or tissue biopsies, which are time-consuming and costly. A newly developed saliva-based platform offers a promising alternative by allowing non-invasive detection of disease biomarkers with high accuracy. In earlier studies, the technology demonstrated strong sensitivity and specificity in identifying tumor mutations, particularly for non-small cell lung cancer, directly from saliva.

Researchers at the UCLA School of Dentistry (Los Angeles, CA, USA) developed a diagnostic platform known as EFIRM (Electric Field-Induced Release and Measurement), a liquid biopsy technology designed to isolate and analyze biomarker signals from biofluids such as saliva. The platform, which builds on more than two decades of research, eliminates the need for complex preparation and uses proprietary electric field-induced techniques to detect disease-related genetic material. The development of EFIRM has led to clinical advances in the detection of salivary biomarkers and has positioned the technology as a potential game changer in early, non-invasive diagnostics. The UCLA School of Dentistry has now entered a three-year sponsored research agreement with Dongwoon Anatech (Seoul, South Korea) to further optimize and clinically validate EFIRM for broader medical applications.

The collaboration will begin by refining protocols for D-SaLife, Dongwoon’s saliva-based glucose monitoring system, in diabetic and non-diabetic patients using samples from hospitals in the U.S. and South Korea. Later phases will focus on developing EFIRM I, a fully automated diagnostic device for cancers such as lung, gastric, and oral cancer, and co-developing EFIRM II, a next-generation, semiconductor-based platform with compact diagnostic cartridges for scalable, point-of-care use. While earlier studies confirmed the system’s clinical accuracy, the current research partnership will allow for expanded testing and device development aimed at real-world deployment. Researchers plan to evaluate performance across different populations, integrate semiconductor technologies for enhanced sensitivity, and eventually bring the system to clinical practice at scale.

"This collaboration reflects our shared vision to make early disease detection faster, simpler, and more accessible around the world," said Dr. David T.W. Wong, professor at the UCLA School of Dentistry. “Dongwoon Anatech’s support brings us closer to realizing EFIRM’s potential in clinical settings.”

Related Links:
UCLA School of Dentistry
Dongwoon Anatech


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.